CML Publications of the Month
As part of our monthly news service we would like to make you aware of important CML publications. From the many papers published in May, Professor Timothy Hughes has selected topical, interesting papers for your perusal. Papers with a clinical, scientific, pediatric and low and middle income country focus are shared.
May 2026
Clinical CML papers
From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia
Hochhaus A et al. Leukemia, May 2026
(epub ahead of print) – open access publication
2001-2026: LEUKEMIA celebrates 25 years of tyrosine kinase inhibitors
Gale RP and Hochhaus A. Leukemia, May 2026
(epub ahead of print)
The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
Perusini MA et al. Leukemia, May 2026
Identification of predictive biomarkers based on cytokine profile for molecular relapse after treatment-free remission in chronic myeloid leukemia patients
Vasconcelos Cordoba B et al. Cells, April 2026 – open access publication
Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic-phase chronic myeloid leukemia in France (PETALs): an open-label, multicentre, randomized phase 3 trial
Nicolini FE et al. Lancet Haematol, May 2026
Olverembatinib-based therapy in patients with transformed chronic myeloid leukemia in lymphoid blast phase or relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: A multicentre retrospective study
Bao M et al. Clin Lymphoma Myeloma Leuk, May 2026
Effects of a high-fat meal on the pharmacokinetics of Olverembatinib in patients with chronic myeloid leukemia
Wang H et al. Clin Transl Sci, May 2026 – open access publication
Real-world outcomes of ponatinib in heavily pretreated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia
Lee S et al. Ann Hematol, May 2026 (epub ahead of print)
Assessment of transitioning from high-potency to low-potency inhibitors in chronic myeloid leukemia (CML) patients: The downgrading-imact (D-IMPACT) project
Abruzzese E et al. Cancers(Basel), May 2026 – open access publication
Long-term safety and efficacy of ponatinib in intolerant chronic myeloid leukemia: Subanalysis of the observational study of Iclusig (ponatinib) treatment in patients with chronic myeloid leukemia in Italy
Breccia M et al. Haematologica, May 2026 (epub ahead of print) – open access publication
BCR-ABL1 transcript ≤10% IS an early molecular response predictor of treatment-free remission eligibility in chronic myeloid leukemia
Rasekh EO et al. Clin Lymphoma Myeloma Leuk, April 2026 (epub ahead of print)
Scientific CML papers
BCR-ABL drives transcriptional reprogramming of chronic myeloid leukemia cells for immune evasion through C/EBPβ
Lu X et al. MedComm (2020), April 2026 eCollection May 2026 – open access publication
Circular RNA in chronic myeloid leukemia
(Commentary on Papaioannou D. et al Blood, May 2026)
Gambacorti-Passerini C. Blood, May 2026
circPCMTD1: a protein-coding circular RNA that regulates DNA damage response in BCR/ABL1-positive leukemias
Papaioannou D et al. Blood, May 2026
Cytogenetic diversity of variant Philadelphia translocations in chronic myeloid leukemia
Tokac AGB et al. Int J Lab Hematol, May 2026 (epub ahead of print)
– open access publication
CD56(+)/CD38(+) neutrophils: Rapid and specific flow cytometric signature for chronic myeloid leukemia
Laganà A et al. Mediterr J Hematol Infect Dis, May 2026 – open access publication
Cracking the CODEX of the leukemic BM microenvironment
(Commentary on Li L. et al Blood, May 2026)
Duarte D et al. Blood, May 2026
High-dimensional spatiotemporal single-cell atlas and 3D imaging of the bone marrow microenvironment during CML progression
Li L et al. Blood, May 2026
Reduced levels of ITGB1 cause activation of P38MAPK-ERK-LYN axis of BCR::ABL1 signaling despite inactivation of the oncoprotein by imatinib – novel resistance mechanism in blast crisis of chronic myeloid leukemia unraveled
Agrawal N et al. Cell Commun Signal, May 2026 (epub ahead of print)
– open access publication
Pediatric CML papers
Therapeutic drug monitoring of imatinib in pediatric chronic myeloid leukemia: Towards practical implementation and interpretation of measured plasma concentrations
Lensker P et al. Clin Pharmacokinet, May 2026 (epub ahead of print)
– open access publication
LMIC CML papers
Impact of the changes in chronic myeloid leukemia classification proposed by the 2022 World Health Organization: a single-center Brazilian study
Emiliano EG et al. Hematol Transfus Cell Ther, May 2026 (epub ahead of print)
– open access publication